Official answer: Syfovre is the first treatment approved to slow a serious form of “dry” age‑related macular degeneration...

TOKYO, Nov.19, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL)...

Official answer: Izervay (avacincaptad pegol) and Syfovre (pegcetacoplan) are injectable treatments for geographic atrophy (GA), a...

Official answer: Izervay (avacincaptad pegol) and Syfovre (pegcetacoplan) are injectable treatments for geographic atrophy (GA), a...

Official answer: Syfovre is the first treatment approved to slow a serious form of “dry” age‑related macular degeneration...

Izervay and Syfovre can slow the progression of this late-stage form of macular degeneration. Find out how they work and if they’re right for you.

Check out SYFOVRE's 75 second TV commercial, 'GA: Take a Stand' from the Auditory & Vision industry. Keep an eye on this page to learn about the songs, characters, and celebrities ...

Editor’s note: This is a developing story. Please check back soon for updates. Under the terms of a definitive agreement, Biogen will acquire Apellis for $41 per share in cash, or approximately $5.6 billion, according to a press release from Biogen. The acquisition includes two FDA-approved commercialized medicines: Syfovre (pegcetacoplan injection) for geographic atrophy and Empaveli (pegcetacoplan) for complement 3 glomerulopathy, primary immune complex membranoproliferative glomerulonephritis and paroxysmal nocturnal hemoglobinuria. The combined net sales for the two treatments in 2025

Largest effects seen in eyes with GA and AMD, dual treatment with pegcetacoplan, VEGF inhibitor

Acquisition will convey two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, together with two uncommon kidney illnesses, and SYFOVRE® FDA-approved in geographic atrophy, an immune-mediated retinal illness Bringing collectively Biogen and Apellis’ commercialization capabilities will maximize the potential of each EMPAVELI® and SYFOVRE®, whereas Apellis’ expertise and experience will speed up Biogen’s entry into nephrology and increase launch readiness for felzartamab, presently in Phase 3…

Editor’s note: This is a developing story. Please check back soon for updates. Under the terms of a definitive agreement, Biogen will acquire Apellis for $41 per share in cash, or approximately $5.6 billion, according to a press release from Biogen. The acquisition includes two FDA-approved commercialized medicines: Syfovre (pegcetacoplan injection) for geographic atrophy and Empaveli (pegcetacoplan) for complement 3 glomerulopathy, primary immune complex membranoproliferative glomerulonephritis and paroxysmal nocturnal hemoglobinuria. The combined net sales for the two treatments in 2025

The current state of treatment for geographic atrophy is marked by two approved therapies that slow GA progression: pegcetacoplan, or Syfovre, from Apellis Pharmaceuticals and avacincaptad pegol, or Izervay, from Astellas. The approvals of these first treatments for GA were an important step in addressing the dearth of options to treat this disease, which is newly diagnosed in 160,000 Americans annually (Rudnicka and colleagues). Although these drugs allow us to treat patients with something rather than nothing, they insufficiently preserve vision in many patients, and data have not shown that

The current state of treatment for geographic atrophy is marked by two approved therapies that slow GA progression: pegcetacoplan, or Syfovre, from Apellis Pharmaceuticals and avacincaptad pegol, or Izervay, from Astellas. The approvals of these first treatments for GA were an important step in addressing the dearth of options to treat this disease, which is newly diagnosed in 160,000 Americans annually (Rudnicka and colleagues). Although these drugs allow us to treat patients with something rather than nothing, they insufficiently preserve vision in many patients, and data have not shown that

Geographic atrophy (GA) is the late form of non-exudative (dry) age-related macular degeneration (AMD), and its relentless progression leads to irreversible vision loss.1,2 In 2023, two complement inhibitors were approved by the U.S. Food and Drug Administration (FDA) after both drugs were shown to slow the growth rate of GA.3 Pegcetacoplan 15mg (Syfovre™, Apellis Pharmaceuticals, Waltham, MA) was approved in February 2023, and inhibits complement component 3 (C3) and C3b. The second complement inhibitor, known as avacincaptad pegol 2mg (ACP; Izervay™, Iveric Bio, an Astellas Company, Parsippany, NJ), was approved in August 2023 and inhibits complement C5.

In this video, Sunir J. Garg, MD, FACS, FASRS, talked about a post hoc analysis of pegcetacoplan clinical trials in geographic atrophy presented at the American Society of Retina Specialists annual meeting. Garg, chief of the retina service at Wills Eye Hospital and professor of ophthalmology at Thomas Jefferson University, said the results of this analysis of Syfovre (pegcetacoplan injection, Biogen) can help determine which patients would benefit the most from treatment as well as help explain to patients their rate of change before vs. after starting treatment. “I think that would be really

Biogen leans on newly acquired Apellis' Empaveli and Syfovre to offset Leqembi's disappointing Alzheimer's sales ahead of Q2 earnings.

(MedPage Today) -- MONTREAL -- Geographic atrophy (GA) had a similar response to the complement inhibitor pegcetacoplan (Syfovre) whether concurrent with neovascular age-related macular degeneration (nAMD) or alone, data from a retina clinical...